Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.65 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.65 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 5/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806895 | 0.89 | REN (0.53) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL2804669 | 0.89 | KLK5 (0.54) | ITGB3ITGA2BACECTSSCTSK | |
| SCHEMBL2804671 | 0.89 | KLK5 (0.54) | ITGB3ITGA2BACECTSSCTSK | |
| SCHEMBL2806897 | 0.89 | REN (0.53) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL10349213 | 0.88 | HDAC8 (0.54) | ITGB3ITGA2BCTSSCTSKCTSL | |
| SCHEMBL335310 | 0.87 | ITGB3 (0.67) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL1311509 | 0.87 | ITGB3 (0.67) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL1062486 | 0.87 | ITGB3 (0.67) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL5065823 | 0.87 | ITGB3 (0.67) | ITGB3ITGA2BACEPTPN1CTSS | |
| SCHEMBL1308867 | 0.87 | ITGB3 (0.67) | ITGB3ITGA2BACEPTPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-0159396-B1 | CARBOXYALKYL PEPTIDE DERIVATIVES | G.D. Searle & Co. (US) | 1990-06-27 | — | — | EP | disclosed |
| US-4568666-A | COLLAGENASE INHIBITORS, ANTIARTJRITIC AGENTS | G. D. SEARLE & CO. (US) | 1986-02-04 | — | — | US | disclosed |
| EP-0159396-A2 | Carboxyalkyl peptide derivatives | G.D. Searle & Co. (US) | 1985-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | HRH4, HRH2, HRH1 | ITGB3 1142/4885ITGA2B 1074/4885ACE 2635/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | ITGB3 1858/4885ITGA2B 1806/4885ACE 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.